Heimdall Insights

Global Idiopathic Pulmonary Fibrosis Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Idiopathic Pulmonary Fibrosis Market was valued at $4.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.2% CAGR, to an estimated market size of $6.5 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global Idiopathic Pulmonary Fibrosis (IPF) market encompasses the pharmacological and non-pharmacological management of a chronic, progressive lung disease characterized by alveolar scarring and irreversible lung function decline. The scope includes antifibrotic agents (nintedanib and pirfenidone), emerging novel therapeutics such as PDE4B and LPA1 inhibitors, and supportive care including oxygen therapy and pulmonary rehabilitation.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Idiopathic Pulmonary Fibrosis Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Tyrosine Kinase Inhibitors (Nintedanib)
  • Pirfenidone
  • Novel & Pipeline Therapies